Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment

Neurology

Volumn 81, Issue 5, 2013, Pages 427-430

  Ullrich, Nicole J ^a   Kieran, Mark W ^a   Miller, David T ^a   Gordon, Leslie B ^a,c   Cho, Yoon Jae ^a   Michelle, V Silvera ^b   Giobbie Hurder, Anita ^d   Neuberg, Donna ^d   Kleinman, Monica E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c BROWN UNIVERSITY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; HUMAN GROWTH HORMONE; LONAFARNIB; TICLOPIDINE; WARFARIN;

ADOLESCENT; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HEADACHE; HUMAN; HUTCHINSON GILFORD PROGERIA SYNDROME; MALE; MIGRAINE; NEUROLOGIC DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGERIA; RECURRENT DISEASE; SCHOOL CHILD; SEIZURE; SYMPTOM; TRANSIENT ISCHEMIC ATTACK;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; NERVOUS SYSTEM DISEASES; PIPERIDINES; PROGERIA; PYRIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84881307604     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31829d85c0     Document Type: Article

References (10)

1. Gordon LB, Brown WT, Collins FS. Hutchinson-Gilford progeria syndrome. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle: University of Washington; 1993-2003. Updated January 6, 2011.
2. Eriksson M, Brown WT, Gordon LB, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003;423:293-298.
3. Merideth MA, Gordon LB, Clauss S, et al. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 2008;358:592-604.
4. Hennekam RC. Hutchinson-Gilford progeria syndrome: review of the phenotype. Am J Med Genet A 2006;140: 2603-2624.
5. Basso AD, Kirschmeier P, Bishop WR. Lipid posttranslational modifications: farnesyl transferase inhibitors. J Lipid Res 2006;47:15-31.
6. Davies BS, Fong LG, Yang SH, Coffinier C, Young SG. The posttranslational processing of prelamin A and disease. Annu Rev Genomics Hum Genet 2009;10:153-174.
7. Capell BC, Erdos MR, Madigan JP, et al. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2005;102:12879-12884.
8. Fong LG, Frost D, Meta M, et al. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 2006;311:1621-1623.
9. Gordon LB, Kleinman ME, Miller DT, et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2012; 109:16666-16671.
10. Silvera VM, Gordon LB, Orbach DB, Campbell SE, Machan JT, Ullrich NJ. Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson-Gilford progeria syndrome. AJNR Am J Neuroradiol 2013;34: 1091-1097.